Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Welireg (belzutifan) to treat advanced, unresectable, or metastatic pheochromocytoma and paraganglioma – Merck Inc

Written by | 16 Jul 2025

Merck Inc., (known as MSD outside of the United States and Canada), announced the FDA  has accepted for priority review a supplemental new drug application (sNDA) seeking approval… read more.

Welireg (belzutifan) receives first European Commission approval for two indications – Merck

Written by | 23 Feb 2025

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved Welireg (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α)… read more.

CHMP positive for Welireg (belzutifan) to treat von Hippel-Lindau disease and renal cell carcinoma – Merck Inc

Written by | 1 Jan 2025

Merck Inc., ( known as MSD outside of the United States and Canada), announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted… read more.

NMPA (China) approves Welireg (belzutifan), for the treatment of adult patients with von Hippel-Lindau disease – Merck Inc

Written by | 17 Dec 2024

Merck Inc. (known as MSD outside of the United States and Canada), announced that the National Medical Products Administration (NMPA) in China has approved Welireg (belzutifan), for the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.